Dogwood Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021


	December 31,		December 31,
	2021		2020
Accrued compensation	$	532,678	$	573,479
Accrued interest on preferred members’ interests		188,085		188,085
Accrued clinical research costs		138,522		—
Accrued director fees		31,000		—
Accrued professional fees		24,100		8,992
Other		7,375		13,548
	$	921,760	$	784,104